Literature DB >> 18186055

Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia.

Iván Chavarría-Siles1, Javier Contreras-Rojas, Elizabeth Hare, Consuelo Walss-Bass, Paulina Quezada, Albana Dassori, Salvador Contreras, Rolando Medina, Mercedes Ramírez, Rodolfo Salazar, Henriette Raventos, Michael A Escamilla.   

Abstract

Functional alterations of components of the endogenous cannabinoid system, in particular of the cannabinoid receptor 1 protein (CB1), are hypothetical contributors to many of the symptoms seen in schizophrenia. Variants within the cannabinoid receptor 1 gene (CNR1) have been shown to be directly associated with the hebephrenic form of schizophrenia in a Japanese population. This finding, however, has yet to be replicated. In the present study we sought to study the same (AAT)n-repeat microsatellite of the CNR1 gene which showed association to hebephrenic schizophrenia in Japan, and to investigate whether this microsatellite showed association to a hebephrenic type of schizophrenia in a family-based association study in a population of the Central Valley of Costa Rica. The Lifetime Dimensions of Psychosis Scale and a best estimate consensus process were utilized to identify subjects with schizophrenia who had an elevated lifetime dimensional score for negative and disorganized symptoms, which we used as a proxy for "hebephrenia." Using the Family Based Association Test we found association of these hebephrenic subjects and the (AAT)n-repeat marker of the CNR1 (multi-allelic P = 0.0368). Our hypothesis that an association with the (AAT)n-repeat marker of CNR1 would not be found with the more general type of schizophrenia was also confirmed. Schizophrenic subjects with prominent lifetime scores for disorganization and negative symptoms (dimension for hebephrenia) are associated with the CNR1 gene and present a type of symptomatology that resembles chronic cannabinoid-induced psychosis. The current finding points to the possibility of different genetic and pathophysiologic mechanisms underlying different types of schizophrenia. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18186055     DOI: 10.1002/ajmg.b.30592

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  31 in total

Review 1.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

2.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Authors:  Beng-Choon Ho; Thomas H Wassink; Steven Ziebell; Nancy C Andreasen
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

Review 3.  Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 4.  The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders.

Authors:  Ismael Galve-Roperh; Javier Palazuelos; Tania Aguado; Manuel Guzmán
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-09       Impact factor: 5.270

Review 5.  Cannabinoids and glial cells: possible mechanism to understand schizophrenia.

Authors:  Valéria de Almeida; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-01       Impact factor: 5.270

Review 6.  What is the mechanism whereby cannabis use increases risk of psychosis?

Authors:  Sonija Luzi; Paul D Morrison; John Powell; Marta di Forti; Robin M Murray
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 7.  Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Authors:  Atsushi Saito; Michael D L Ballinger; Mikhail V Pletnikov; Dean F Wong; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

9.  Accessing Gene Expression in Treatment-Resistant Schizophrenia.

Authors:  Patricia N Moretti; Vanessa K Ota; Eduardo S Gouvea; Mariana Pedrini; Marcos L Santoro; Fernanda Talarico; Leticia M Spindola; Carolina Muniz Carvalho; Cristiano Noto; Gabriela Xavier; Elisa Brietzke; Ary Gadelha; Rodrigo Bressan; Jair Mari; Sintia Belangero
Journal:  Mol Neurobiol       Date:  2018-01-26       Impact factor: 5.590

Review 10.  Role of cannabis and endocannabinoids in the genesis of schizophrenia.

Authors:  Emilio Fernandez-Espejo; Maria-Paz Viveros; Luis Núñez; Bart A Ellenbroek; Fernando Rodriguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2009-07-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.